22 min listen
Why the FDA May Need to Rethink Its Approach to Gene and Cell Therapy
FromThe Bio Report
ratings:
Length:
27 minutes
Released:
Sep 21, 2017
Format:
Podcast episode
Description
Regenerative medicine is rapidly moving from the lab to the clinic, but as life-saving therapies advance to the marketplace, there are questions about whether the U.S. Food and Drug Administration needs to modernize its regulatory approach to gene and cell therapies. We spoke to Michael Werner, executive director of the Alliance for Regenerative Medicine, about the state of the industry, the regulatory environment today, and whether it will ultimately be payers who are more demanding of data to convince them of the worth of a therapy.
Released:
Sep 21, 2017
Format:
Podcast episode
Titles in the series (100)
The Year in Biotech So Far and What’s Ahead: The biotech sector surged in the first half of the year despite volatile markets. M&A and financing continued to be robust as EvaluatePharma weighed in with its Pharma & Biotech Half-Year Report. We spoke to Jonathan Gardner, deputy news editor of EP... by The Bio Report